mRNA疫苗编码VZV gE抗原在非人灵长类中的免疫原性与佐剂亚单位疫苗相当且优于减毒活疫苗
本研究在非人灵长类中比较了三种带状疱疹疫苗平台的体液和细胞免疫应答:脂质纳米颗粒包裹的mRNA编码VZV gE抗原、减毒活疫苗和佐剂gE亚单位蛋白疫苗。单剂100-200 μg或两剂50 μg mRNA疫苗的应答幅度与两剂50 μg蛋白疫苗相当,且两者均显著高于减毒活疫苗。三种疫苗的抗体滴度衰减斜率大致相似,提示峰值免疫原性决定免疫持久性。
要点
- mRNA疫苗单剂100-200 μg或两剂50 μg的免疫应答与两剂50 μg佐剂蛋白疫苗相当。
- mRNA疫苗和佐剂蛋白疫苗诱导的应答均显著高于减毒活疫苗。
- 三种疫苗的抗体衰减斜率相似,峰值免疫原性决定应答持久性。
核心结论
- VZV gE mRNA/LNP平台在非人灵长类中诱导的免疫应答与佐剂亚单位疫苗相当,且优于减毒活疫苗。
研究设计与样本
- 研究使用非人灵长类评估三种疫苗平台的体液和细胞免疫应答:VZV gE mRNA/LNP、VZV减毒活疫苗和佐剂VZV gE亚单位蛋白疫苗。
主要发现
- 单剂100-200 μg或两剂50 μg VZV gE mRNA/LNP的应答幅度与两剂50 μg佐剂蛋白疫苗相当。
- VZV gE mRNA/LNP和佐剂蛋白疫苗诱导的应答均显著高于VZV减毒活疫苗。
- 三种疫苗的VZV特异性抗体滴度衰减斜率大致相似。
- 非人灵长类中VZV减毒活疫苗和佐剂蛋白疫苗的免疫原性与人体临床试验数据高度相似。
临床怎么用
- 非人灵长类模型可用于评估带状疱疹疫苗的临床前免疫原性。
- mRNA疫苗平台有望作为带状疱疹预防的候选策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Shingles is a painful, blistering rash caused by reactivation of latent varicella-zoster virus (VZV) and most frequently occurs in elderly and immunocompromised individuals. Currently, two approved vaccines for the prevention of shingles are on the market, a live attenuated virus vaccine ZOSTAVAX® (Merck & Co., Inc., Kenilworth, NJ, USA) and an AS01B adjuvanted subunit protein vaccine Shingrix™ (Glaxo Smith Kline, Rockville, MD, USA). Human clinical immunogenicity and vaccine efficacy data is available for these two benchmark vaccines, offering a unique opportunity for comparative analyses with novel vaccine platforms and animal model translatability studies. The studies presented here utilized non-human primates (NHP) to evaluate humoral and cellular immune response by three vaccine modalities: the new platform of lipid nanoparticle (LNP) formulated mRNA encoding VZV gE antigen (VZV gE mRNA/LNP) as compared with well-established platforms of live attenuated VZV (VZV LAV) and adjuvanted VZV gE subunit protein (VZV gE protein/adjuvant). The magnitude of response to vaccination with a single 100-200 μg mRNA dose or two 50 μg mRNA doses of VZV gE mRNA/LNP were comparable to two 50 μg protein doses of VZV gE protein/adjuvant, suggesting the VZV gE mRNA/LNP platform has the potential to elicit a robust immune response, and both modalities generated markedly higher responses than VZV LAV. Additionally, the slopes of decay for VZV-specific antibody titers were roughly similar across all three vaccines, indicating the magnitude of peak immunogenicity was the driving force in determining immune response longevity. Finally, vaccine-induced immunogenicity with VZV LAV and VZV gE protein/adjuvant in NHP closely resembled human clinical trials immune response data for ZOSTAVAX® and Shingrix™, helping to validate NHP as an appropriate preclinical model for evaluating these vaccines.
引用
- Monslow MA, Elbashir S, Sullivan NL, et al. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine. 2020. PMID: 32703745. doi:10.1016/j.vaccine.2020.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。